Pulmonary hypertension (PH) is a complex and often misunderstood condition. This article aims to provide a comprehensive overview of PH, its pathophysiology, clinical presentation, diagnosis, and management.
PH is characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, leading to right heart failure. The pathophysiology involves vasoconstriction, vascular remodeling, and thrombosis in situ. It is classified into five groups based on the underlying cause, each having distinct pathophysiological mechanisms.
PH often presents nonspecifically, making it challenging to diagnose. Common symptoms include dyspnea, fatigue, chest pain, and syncope. Physical examination may reveal signs of right heart failure, including jugular venous distention, hepatomegaly, and peripheral edema.
Diagnosis involves a high index of suspicion, given the nonspecific presentation. Initial evaluation includes echocardiography, followed by right heart catheterization - the gold standard for diagnosis. Additional tests help classify PH and identify the underlying cause.
Management strategies are tailored according to the PH classification. General measures include supplemental oxygen, diuretics, and anticoagulation. Specific therapies target pathophysiological mechanisms, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
PH is a complex condition requiring a comprehensive understanding for effective management. Early recognition, accurate classification, and appropriate management can significantly improve patient outcomes. As healthcare professionals, continuous learning and staying updated on recent advancements are crucial in managing this challenging condition.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation